WO2007084857A3 - Methods and compositions for treating cell proliferative disorders - Google Patents
Methods and compositions for treating cell proliferative disorders Download PDFInfo
- Publication number
- WO2007084857A3 WO2007084857A3 PCT/US2007/060504 US2007060504W WO2007084857A3 WO 2007084857 A3 WO2007084857 A3 WO 2007084857A3 US 2007060504 W US2007060504 W US 2007060504W WO 2007084857 A3 WO2007084857 A3 WO 2007084857A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell proliferative
- proliferative disorders
- compositions
- methods
- treating cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides methods for treating and preventing cell proliferative disorders and conditions comprising administering to a subject resveratrol or an analog thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/087,631 US20090182003A1 (en) | 2006-01-13 | 2007-01-12 | Methods and Compositions for Treatment Cell Proliferative Disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75912406P | 2006-01-13 | 2006-01-13 | |
US60/759,124 | 2006-01-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007084857A2 WO2007084857A2 (en) | 2007-07-26 |
WO2007084857A3 true WO2007084857A3 (en) | 2007-09-07 |
Family
ID=38098586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/060504 WO2007084857A2 (en) | 2006-01-13 | 2007-01-12 | Methods and compositions for treating cell proliferative disorders |
Country Status (2)
Country | Link |
---|---|
US (1) | US20090182003A1 (en) |
WO (1) | WO2007084857A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947733B2 (en) | 2007-07-31 | 2011-05-24 | Limerick Biopharma | Phosphorylated pyrone analogs and methods |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110082189A1 (en) * | 2007-10-23 | 2011-04-07 | President And Fellows Of Harvard College | Use of compounds activating sirt-3 for mimicking exercise |
TW201000099A (en) | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
BRPI1003661A2 (en) * | 2010-09-15 | 2013-01-08 | Libbs Farmaceutica Ltda | pharmaceutical combination to treat and / or prevent fibroid and / or endometriosis, use of resveratrol and progestogen, pharmaceutical composition for treatment and / or prevention of fibroid and / or endometriosis drug for treatment and / or prevention of fibroid and / or endometriosis, kit and Method for the treatment and / or prevention of fibroid and / or endometriosis |
CN103765212A (en) * | 2011-06-27 | 2014-04-30 | 杰克逊实验室 | Methods and compositions for treatment of cancer and autoimmune disease |
US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
EA035929B1 (en) | 2013-01-15 | 2020-09-02 | Инсайт Холдингс Корпорейшн | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDES USEFUL AS Pim KINASE INHIBITORS |
MX2016002367A (en) | 2013-08-23 | 2016-10-28 | Incyte Corp | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors. |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
TW201702218A (en) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
CN105111263B (en) * | 2015-08-31 | 2017-07-28 | 南阳师范学院 | Flavone compound isolated and purified from shepherd's purse and its production and use |
TWI734699B (en) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Salts of a pim kinase inhibitor |
TW201718546A (en) | 2015-10-02 | 2017-06-01 | 英塞特公司 | Heterocyclic compounds useful as PIM kinase inhibitors |
CN108395461B (en) * | 2017-02-07 | 2022-01-07 | 浙江康恩贝制药股份有限公司 | 7, 4' -O-beta-D-glucose morin glycoside, preparation thereof and application thereof in preparing anti-inflammatory drugs |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001042231A2 (en) * | 1999-12-06 | 2001-06-14 | Welichem Biotech Inc. | Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors |
WO2002017959A2 (en) * | 2000-08-28 | 2002-03-07 | Wisconsin Alumni Research Foundation | Immunosuppression using piceatannol and a calcineurin inhibitor |
WO2003039557A1 (en) * | 2001-11-02 | 2003-05-15 | The Regents Of The University Of California | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection |
WO2003049725A2 (en) * | 2001-12-07 | 2003-06-19 | Ziegler Randy H | Compositions for the treatment of lupus, other rheumatic diseases and joint diseases |
WO2003068202A1 (en) * | 2002-02-15 | 2003-08-21 | Dsm Ip Assets B.V. | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
US20040258674A1 (en) * | 2003-04-10 | 2004-12-23 | Thunder Jalili | Quercetin supplementation to treat hypertenstion |
WO2004112763A2 (en) * | 2003-05-21 | 2004-12-29 | Board Of Regents, The University Of Texas System | Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
WO2005089066A2 (en) * | 2004-03-23 | 2005-09-29 | Rimonest Ltd. | Pharmaceutical compositions, methods of formulation thereof and methods of use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040259816A1 (en) * | 2002-10-01 | 2004-12-23 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
-
2007
- 2007-01-12 US US12/087,631 patent/US20090182003A1/en not_active Abandoned
- 2007-01-12 WO PCT/US2007/060504 patent/WO2007084857A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001042231A2 (en) * | 1999-12-06 | 2001-06-14 | Welichem Biotech Inc. | Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors |
WO2002017959A2 (en) * | 2000-08-28 | 2002-03-07 | Wisconsin Alumni Research Foundation | Immunosuppression using piceatannol and a calcineurin inhibitor |
WO2003039557A1 (en) * | 2001-11-02 | 2003-05-15 | The Regents Of The University Of California | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection |
WO2003049725A2 (en) * | 2001-12-07 | 2003-06-19 | Ziegler Randy H | Compositions for the treatment of lupus, other rheumatic diseases and joint diseases |
WO2003068202A1 (en) * | 2002-02-15 | 2003-08-21 | Dsm Ip Assets B.V. | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
US20040258674A1 (en) * | 2003-04-10 | 2004-12-23 | Thunder Jalili | Quercetin supplementation to treat hypertenstion |
WO2004112763A2 (en) * | 2003-05-21 | 2004-12-29 | Board Of Regents, The University Of Texas System | Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
WO2005089066A2 (en) * | 2004-03-23 | 2005-09-29 | Rimonest Ltd. | Pharmaceutical compositions, methods of formulation thereof and methods of use thereof |
Non-Patent Citations (12)
Title |
---|
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 424A, ISSN: 0006-4971 * |
BLOOD, vol. 106, no. 11, Part 2, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 250B, ISSN: 0006-4971 * |
BYULLETEN EKSPERIMENTAL'NOI BIOLOGII I MEDITSINY , 73(6), 80-3 CODEN: BEBMAE; ISSN: 0365-9615, 1972 * |
CAO ZONGXIAN ET AL: "trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 AUG 2004, vol. 10, no. 15, 1 August 2004 (2004-08-01), pages 5253 - 5263, XP002437587, ISSN: 1078-0432 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), BERTONI FRANCESCO ET AL: "Inhibition of the B cell associated tyrosine kinase SYK as a potential therapeutic target in aggressive lymphomas.", XP002437594, Database accession no. PREV200600183839 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), FABER ANTHONY C ET AL: "Resveratrol induces cell cycle arrest in the OCI-LY18 B-cell lymphoma.", XP002437593, Database accession no. PREV200600133089 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 May 1984 (1984-05-12), VERMENICHEV, S. M. ET AL: "Participation of catechol amines in the antineoplastic action of leukoephdin and quercetin", XP002437592, retrieved from STN Database accession no. 1972:496957 * |
FOX CASEY J ET AL: "The Pim kinases control rapamycin-resistant T cell survival and activation", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 201, no. 2, 17 January 2005 (2005-01-17), pages 259 - 266, XP002437586, ISSN: 0022-1007 * |
JAZIREHI ALI R ET AL: "Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.", MOLECULAR CANCER THERAPEUTICS, vol. 3, no. 1, January 2004 (2004-01-01), pages 71 - 84, XP002437584, ISSN: 1535-7163 * |
LI H-L ET AL: "Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways", FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER SCIENCE, XX, vol. 38, no. 2, 15 January 2005 (2005-01-15), pages 243 - 257, XP004696941, ISSN: 0891-5849 * |
LIESVELD JANE L ET AL: "Flavonoid effects on normal and leukemic cells.", LEUKEMIA RESEARCH, vol. 27, no. 6, June 2003 (2003-06-01), pages 517 - 527, XP002437585, ISSN: 0145-2126 * |
ROMAN VIVIANA ET AL: "Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia", BRITISH JOURNAL OF HAEMATOLOGY, vol. 117, no. 4, June 2002 (2002-06-01), pages 842 - 851, XP002437583, ISSN: 0007-1048 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947733B2 (en) | 2007-07-31 | 2011-05-24 | Limerick Biopharma | Phosphorylated pyrone analogs and methods |
Also Published As
Publication number | Publication date |
---|---|
US20090182003A1 (en) | 2009-07-16 |
WO2007084857A2 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007084857A3 (en) | Methods and compositions for treating cell proliferative disorders | |
IL277322A (en) | Compositions and methods for treating collagen-mediated diseases | |
HRP20190378T1 (en) | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
WO2009089260A3 (en) | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases | |
WO2010060937A3 (en) | Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor | |
WO2011142858A3 (en) | Chlorotoxin variants, conjugates, and methods for their use | |
TWI348891B (en) | Composition for preventing plant diseases and method for preventing the diseases | |
EP1883416A4 (en) | Compositions and methods for the prevention and treatment of conditions associated with inflammation | |
IL184312A0 (en) | Herbal compositions for the treatment of diabetes and/or conditions associated therewith | |
MY172372A (en) | Compositions and methods for lowering triglycerides | |
WO2007111994A3 (en) | Compounds and methods for treatment of disorders associated with er stress | |
WO2009089494A3 (en) | Pharmaceutical compositions | |
HK1166983A1 (en) | Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith | |
WO2007145704A3 (en) | Gemcitabine combination therapy | |
WO2009120810A3 (en) | Neurodegenerative disorders | |
WO2009009417A3 (en) | Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion | |
WO2007101161A8 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2010068815A3 (en) | Compositions and methods for treating cellular proliferative disorders | |
WO2010141956A3 (en) | Methods and compositions for the treatment of cancer | |
HUE047692T2 (en) | Pharmaceutical compositions and methods for stabilizing the same | |
WO2011014520A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
EP2004164A4 (en) | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | |
EP2005964A4 (en) | The medicament for treating hyperphospheremia and preparation thereof | |
WO2011011733A3 (en) | Factor replacement therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12087631 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07710112 Country of ref document: EP Kind code of ref document: A2 |